Immunity, inflammation and disease · 2025
Clinical Evaluation of the Healgen Rapid COVID-19 Antigen Test as a Point-of-Care Diagnostic Tool.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Young Stephen A, Zhang Hua, Rodriguez Jose, Mishkin David, Paine Ward, Seyfried Li, Hargrove LaTisha, Broyles Dennis L, Lindberg Chermaen, Purushothaman Anurag, House Stacey
Аннотация
BACKGROUND: Development of readily available Rapid COVID-19 Antigen tests essential for promptly identifying SARS-CoV2 infection and preventing its spread.
METHODS: This study evaluated the clinical performance of the Healgen Rapid COVID-19 antigen test as a point-of-care diagnostic tool with 806 evaluable subjects who were within 6 days post-symptom onset. The results from the Healgen test were compared to the results from Emergency Use Authorization (EUA) approved SARS-CoV-2 RT-PCR tests.
RESULTS: Out of the 806 evaluable subjects, 140 tested positive and 640 tested negative for SARS-CoV-2 with the Healgen COVID-19 test, showing good agreement with the EUA RT-PCR results. There were 26 subjects with discordant results, of which 24 were negative according to the Healgen test but positive according to the RT-PCR test, while 2 were positive by the Healgen test but negative by the EUA-PCR test. The positive percent agreement (PPA) and negative percent agreement (NPA) were 85.4% and 99.7%, respectively. Additionally, the Healgen COVID-19 test detected 34 cases (60.7%) out of 56 weak positive cases (based on Ct values of ≥ 30 by the EUA PCR test), demonstrating good detection capability of the test.
CONCLUSIONS: The Healgen Rapid COVID-19 antigen detection test demonstrated good performance in terms of PPA and NPA when compared to the EUA RT-PCR assays and has potential as a diagnostic tool for SARS-CoV-2.
METHODS: This study evaluated the clinical performance of the Healgen Rapid COVID-19 antigen test as a point-of-care diagnostic tool with 806 evaluable subjects who were within 6 days post-symptom onset. The results from the Healgen test were compared to the results from Emergency Use Authorization (EUA) approved SARS-CoV-2 RT-PCR tests.
RESULTS: Out of the 806 evaluable subjects, 140 tested positive and 640 tested negative for SARS-CoV-2 with the Healgen COVID-19 test, showing good agreement with the EUA RT-PCR results. There were 26 subjects with discordant results, of which 24 were negative according to the Healgen test but positive according to the RT-PCR test, while 2 were positive by the Healgen test but negative by the EUA-PCR test. The positive percent agreement (PPA) and negative percent agreement (NPA) were 85.4% and 99.7%, respectively. Additionally, the Healgen COVID-19 test detected 34 cases (60.7%) out of 56 weak positive cases (based on Ct values of ≥ 30 by the EUA PCR test), demonstrating good detection capability of the test.
CONCLUSIONS: The Healgen Rapid COVID-19 antigen detection test demonstrated good performance in terms of PPA and NPA when compared to the EUA RT-PCR assays and has potential as a diagnostic tool for SARS-CoV-2.